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Abstract
Purpose Panobinostat, a potent pan-deacetylase inhibitor, im-
proved progression-free survival (PFS) in patients with re-
lapsed and refractory multiple myeloma when combined with
bortezomib and dexamethasone in a phase 3 trial, PANO-
RAMA-1. This study aims to explore exposure–response re-
lationship for panobinostat in this combination in a phase 1
trial, B2207 and contrast with data from historical single-agent
studies.
Methods Panobinostat plasma concentration–time profiles
were obtained in patients from PANORAMA-1 (n=12) and
B2207 (n=12) trials. Overall response rates (ORR) and major
adverse events (AE) by panobinostat exposure were investi-
gated in the B2207 trial. Panobinostat PK data from combina-
tion trials were contrasted with data from single-agent studies.
Results At maximum tolerated dose (MTD), the geometric
mean of panobinostat area under curve from 0 to 24 h
(AUC0-24) was 47.5 ng h/mL (77 % CV), and maximum
plasma concentration (Cmax) was 8.1 ng/mL (90 % CV).
These values were comparable with exposure data obtained
in PANORAMA-1, but were 20 % lower than those without
dexamethasone, and ∼50 % lower from single-agent trials,
likely due to enzyme induction by dexamethasone. Higher
levels of panobinostat exposure were associated with higher
response rates and higher incidences of diarrhea and
thrombocytopenia.
Conclusions Apparent panobinostat exposure–AE and expo-
sure–ORR relationships were observed when combined with
bortezomib and dexamethasone in the treatment of patients
with relapsed and refractory multiple myeloma. The addition
of dexamethasone facilitated best response even though plas-
ma exposure of panobinostat was reduced. Combination with
a strong enzyme inducer should be avoided in future trials to
prevent further reduction of panobinostat exposure.
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Introduction
Panobinostat is a pan-histone deacetylase inhibitor (HDACi)
with low nanomolar activity against class I, II, and IV histone
deacetylases [1, 2]. Panobinostat (Farydak®) in combination
with bortezomib and dexamethasone was recently approved in
the USA, European Union, and Japan, for treatment of re-
lapsed or relapsed and refractory multiple myeloma, in pa-
tients who had received at least 2 prior regimens, including
bortezomib and an immunomodulatory agent. The anticancer
activity of panobinostat is thought to be due to its effect on
epigenetic modulation and inhibition of proteolytic
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degradation pathways [3, 4]. Panobinostat showed synergistic
antimyeloma activity when combined with the proteasome
inhibitor, bortezomib, in cell lines in vitro [5, 6], and more
recently, this combination showed a clinically relevant exten-
sion in progression-free survival in a phase 3 clinical trial
(PANORAMA-1), in patients with relapsed and relapsed/
refractory multiple myeloma [7]. Previously, an open-label,
phase 1b trial (B2207), with escalating doses of panobinostat
and bortezomib with or without dexamethasone, was carried
out in order to determine the maximum tolerated dose (MTD)
and recommended dose for this combination [8]. Both the
trials provided data on panobinostat exposure in combination
with dexamethasone and bortezomib.
The safety and pharmacokinetic (PK) profile of single-
agent panobinostat have been studied in multiple phase 1
and 2 trials [9–12]. Drug metabolism and distribution have
been characterized using trace radiolabeled panobinostat
[10]. Other studies addressed changes in panobinostat PK or
safety in patients with impaired hepatic or renal function [13,
14], interactions of panobinostat with a sensitive CYP2D6
substrate, a strong CYP3A inhibitor, and effect of food on
panobinostat disposition [15–17].
The objective of the current study is to characterize the PK
of panobinostat in the combination regimen with dexametha-
sone and bortezomib (PANORAMA-1 and B2207 clinical
trials [7, 8]), in comparison with the PK profile of the single
agent. The relationship of panobinostat exposures to overall
response rate (ORR) per International Myeloma Working
Group (IMWG) criteria and frequency of occurrence of grade
3 or 4 adverse events (AEs) in the phase 1b trial B2207 were
also analyzed.
Clinical pharmacology of single-agent panobinostat
Panobinostat is rapidly absorbed following oral administration
with a median time (Tmax) to reach maximum plasma con-
centration (Cmax) of about 2 h. Mean concentration–time
profiles after a 20 mg/m2 iv or 20 mg oral administration
can be found in Fig. 1 [10]. The effective half-life (T1/2) of
panobinostat is approximately 16 h based on the rate of accu-
mulation of approximately 1.1-fold observed in single-agent
trial [10], and steady state is reached after the third dose in a
thrice-weekly (tiw) dosing schedule [10]. It is extensively me-
tabolized through both CYP and non-CYP mediated path-
ways; the fraction of the radiolabeled dose recovered in the
feces and urine was 44 to 77 % and 29 to 51 %, respectively
[10]. Unchanged panobinostat in the feces accounted for
<3.5% of the administered dose, suggesting good oral absorp-
tion [10]. Pharmacokinetics of panobinostat is approximately
linear in the tested dose range between 10 and 30mg. The oral
bioavailability of panobinostat is marginally affected by fed or
fasting state of the patient, and the food effect is not consid-
ered clinically relevant [17].
Panobinostat is biotransformed into over 70 metabolites,
none of which showed pharmacologic activity at concentra-
tions of up to 30 μM [10]. Panobinostat shows a weak drug–
drug interaction potential. Ketoconazole, a strong CYP3A in-
hibitor, increased the systemic exposure of panobinostat by
80 % in cancer patients [16]. Panobinostat increased the sys-
temic exposure of a sensitive CYP2D6 substrate, dextrome-
thorphan by 60 %, in cancer patients [15]. Mild, moderate, or
severe renal impairment did not alter the plasma exposure of
panobinostat in patients with solid tumors [14]; however, mild
and moderate hepatic impairment increased panobinostat ex-
posure by 43 and 105 %, respectively [13].
Methods
Multiple clinical trials with panobinostat PK are compared in
the current analysis. All patients in the trials gave written
informed consent for participation, and the study protocols
were approved by the institutional review board/independent
ethics committee/research ethics board at each study site. The
clinical trials PANORAMA-1 [7] and B2207 [8] are registered
at ClinicalTrials.gov with the identifier numbers
NCT01023308 and NCT00532389, respectively. A detailed
description of the study design and key results for
panobinostat single-agent trials are available in the published
literature [9, 11, 12, 18].
Study design
B2207 clinical trial
This was an open-label, phase 1b study done in 2 phases: a
dose-escalation phase (using 10–30 mg oral panobinostat and
1 or 1.3 mg/m2 intravenous [IV] bortezomib) to determine
MTD and a dose-expansion phase at MTD to determine safety
and efficacy. The MTD was 20 mg tiw panobinostat and
1.3 mg/m2 twice-weekly (biw) bortezomib. In the dose-
expansion phase, patients were treated at MTD for eight, 3-
week cycles (2 weeks of panobinostat and bortezomib therapy
and 1 week with no drugs). In addition, 20-mg oral dexameth-
asone was added starting cycle 2 on the day of and the day
after bortezomib therapy. After 8 cycles, patients could dis-
continue bortezomib/dexamethasone and continue on
panobinosta t a lone unt i l d isease progress ion or
discontinuation.
PANORAMA-1 clinical trial
This was a phase 3, randomized, double-blind, placebo-
controlled trial that assessed efficacy of panobinostat
versus placebo plus bortezomib and dexamethasone at
the MTD dose and schedule, determined in B2207 trial,
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in 2 treatment phases. Each phase was of 24 weeks
duration with treatment phase 1 consisting of eight, 3-
week cycles and treatment phase 2 consisting of four, 6-
week cycles. Those patients who had received clinical
benefit in treatment phase 1 could proceed to treatment
phase 2, in which the bortezomib dose schedule was
dropped to once weekly (qw) instead of biw.
PK assessment
B2207 trial
PK assessment was carried out in the dose escalation
and dose expansion parts of the trial for both
panobinostat and bortezomib. In the dose escalation
part, PK samples were collected on cycle 1, day 8,
and cycle 1, day 15 at pre-dose, and various intervals
post-dose up to 48 h. In the dose expansion part, an
initial PK sampling was done on cycle 1 day 8 to ob-
tain PK data for panobinostat and bortezomib in the
absence of dexamethasone. Subsequent PK sampling
was done on cycle 2, day 8 to obtain PK data for
panobinostat and bortezomib in the presence of dexa-
methasone. Concentration–time profiles of dexametha-
sone were not assessed. Blood samples were taken at
pre-dose (for both drugs): at 5 and 15 min (for
bortezomib alone) and at 0.5, 1, 2, 3, 4, 6, 8, 24, and
48 h post-dose (for both drugs). Plasma panobinostat
concentrations were measured using a validated liquid
chromatography tandem mass spectrometry (LC-MS/
MS) method with lower limit of quantification (LLOQ)
of 0.1 ng/mL [10, 19].
PANORAMA-1 trial
In this study, plasma samples for panobinostat and
bortezomib were collected in a subset of Asian patients.
Blood samples were taken at scheduled time points (cy-
cle 1, day 1, and cycle 1 day 8 at pre-dose and at 0.5,
1, 2, 3, 4, 8, 24, and 48 h post-dose) for PK analysis.
Pharmacokinetic analysis
Pharmacokinetic analyses were conducted in WinNonlin Pro
version 5.2 (Pharsight, Gary, NC) to derive PK parameters
such as Cmax and Tmax for panobinostat and bortezomib,
total body clearance (CL/F), apparent volume of distribution
(Vz/F), area under the curve from time zero to 24 h (AUC0-
24), area under the curve from time zero to infinity (AUC0-
inf), and terminal half-life (T1/2).
Efficacy and safety assessment
The two combination studies, B2207 and PANORAMA-1,
reported efficacy data in patients with relapsed and refractory
multiple myeloma [7, 8]. In the current analysis, exposure–
efficacy relationship was explored using the efficacy data
(ORR based on IMWG criteria) from the B2207 trial. Expo-
sure–safety relationship was also characterized for the dose
ranges of 10 to 30 mg panobinostat and 1 or 1.3 mg/m2
bortezomib in the B2207 trial.
Results
The baseline demographic data for the subset of patients with
PK information from PANORAMA-1 and B2207 clinical tri-
als are summarized in Table 1. The median age for patients in
the PANORAMA-1 trial was 63 years and for patients in the
B2207 was 62 years. The B2207 trial had 19 centers in Aus-
tralia, Europe, and North America [8], and the PANORAMA-
1 study had 215 centers in 34 countries, including Japan [7].
The PK data for PANORAMA-1 study were provided only
from centers in Japan. Both trials enrolled patients with a
median of 2 prior therapies, and ≥50 % of patients had
bortezomib in their prior line of therapy.
Dexamethasone effect on panobinostat exposures
B2207 study used escalating doses of panobinostat (10, 20,
25, and 30 mg) in combination with 1.0 or 1.3 mg/m2
bortezomib. In the dose-expansion phase, 20 mg panobinostat
plus 1.3 mg/m2 bortezomib was used in the absence (cycle 1,
Fig. 1 Plasma concentration-
time profiles of panobinostat
following a single 20 mg/m2 IV
dose and a single 20 mg oral dose
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day 8) or presence (cycle 2, day 8) of 20 mg dexamethasone.
Pharmacokinetic parameters fromB2207 trial are summarized
in Table 2. Geometric mean (percent coefficient of variation,
CV) of panobinostat exposure (AUC0-24) determined in the
absence of dexamethasone on cycle 1 day 8 was 61.8 (60.9 %)
ng h/mL and in the presence of dexamethasone (cycle 2, day
8), in the same patient population was 47.5 (76.8 %) ng h/mL.
The maximum plasma concentration (Cmax) of panobinostat
on cycle 1 day 8 in the absence of dexamethasone was 9.5
(60.4 %) ng/mL and in the presence of dexamethasone on
cycle 2, day 8 was 8.1 (90.3 %) ng/mL. In the presence of
dexamethasone, an approximately 20 % lower panobinostat
exposure was observed, with no apparent difference in the
half-life (Table 3).
In single-agent studies [12, 18], PK data were taken from
patients having an eligible record of multiple oral doses of
20 mg (tiw) panobinostat for comparison. Table 3 shows that
the T1/2 (16 h) and Tmax (1–2 h) of panobinostat are the same
between historical single-agent trials and the 2 combination
trials. However, lower panobinostat exposures (AUC0-24)
were seen in both B2207 and PANORAMA-1 compared to
single-agent studies. In the B2207 study, the geometric mean
of AUC0-24 was 48 (77 %) ng·h/mL, and in PANORAMA-1
study, it was 95 (28 %) ng·h/mL, with the range of values
largely overlap (Fig. 2). In single-agent studies, the geometric
mean (%CV) of AUC0-24was higher at 139 (71%) ng h/mL.
Relationship between panobinostat exposures
and response in the B2207 study
A summary of efficacy data and PK parameters (AUC0-24
and Cmax) for individual doses of panobinostat is given in
Table 4. The rates of ORR and grade 3 or 4 diarrhea and
thrombocytopenia are plotted against panobinostat exposures
for individual doses of panobinostat in Fig. 3. In the B2207
study, during dose-escalation phase, no dexamethasone was
administered to patients. The ORR defined as greater than or
equal to partial response (PR) increased with increasing dose
of bortezomib (from 1.0 to 1.3 mg/m2) and panobinostat (10–
30 mg). Two (28.6 %) patients showed a response of ORR≥
PR at the dose of 20 mg panobinostat and 1 mg/m2
bortezomib, whereas 9 (52.9 %) patients achieved ORR≥PR
upon increasing the dose of bortezomib from 1 to 1.3 mg/m2
and keeping panobinostat dose constant at 20mg. The number
of patients with ORR≥PR was 11 (73.3 %) for the group that
received 20 mg dexamethasone in addition to the combination
of panobinostat 20 mg and bortezomib 1.3 mg/m2 (Table 4).
ORR appears to plateau at the dose of 20 mg (tiw)
panobinostat and 1.3 mg/m2 (biw) bortezomib in the dose-
escalation phase (Fig. 3).
Association of panobinostat exposures
with thrombocytopenia in the B2207 study
During the dose-escalation phase of the B2207 study, incidences
of grade 3 or 4 thrombocytopenia were >80 % (Table 4 and
Fig. 3). During the dose-expansion phase (20 mg tiw
Table 1 Patient characteristics
and baseline demographics for
B2207 and PANORAMA-1
studies
Demographic or clinical characteristics B2207 (dose-expansion phase) PANORAMA-1 (Japan subset)
PAN+BTZ+Dex PAN+BTZ+Dex
N=15 N=18
Median age in years (range) 62 (48–71) 63.5 (41–75)
ECOG PS
0 n (%) 12 (80 %) 13 (72.2 %)
1 n (%) 3 (20 %) 5 (27.8 %)
Prior therapies median (range) 2 (1–7) 2 (1–3)
Prior therapy
Prior BTZ, n (%) 11 (73.3 %) 9 (50 %)
Refractory to BTZ, n (%) 4 (26.7 %) NA
Prior lenalidomide, n (%) 7 (46.7 %) 2 (11.1 %)
Prior thalidomide, n (%) 5 (33.3 %) 3 (16.7 %)
Prior melphalan, n (%) 1 (6.7 %) 16 (88.9 %)
Prior ASCT, n (%) 14 (93.3 %) NA
ASCT autologous stem cell transplant, PAN panobinostat, BTZ bortezomib, Dex dexamethasone, ECOG PS
Eastern Cooperative Oncology Group Performance Status score
Table 2 PK parameters for panobinostat in B2207 trial
PK parameters Cycle 1 day 8 (n=15)
in the absence of Dex
Cycle 2 day 8 (n=12)
in the presence of Dex
AUC0-24 (ng h/mL) 61.8 (60.9) 47.5 (76.8)
Cmax (ng/mL) 9.5 (60.4) 8.1 (90.3)
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panobinostat and 1.3 mg/m2 biw bortezomib) that used a 2-
week dosing schedule and 1-week rest with no drugs, the inci-
dence of grade 3 or 4 thrombocytopenia dropped to 66.7 %. In
the dose-escalation phase, the rate of grade 3 or 4 thrombocyto-
penia (85.7 %) was the same for 10 mg (tiw) and 20 mg (tiw)
panobinostat dose at a constant bortezomib dose of 1.0 mg/m2
(biw). At the higher bortezomib dose of 1.3 mg/m2 (biw), the
rates of grade 3 or 4 thrombocytopenia were 82.4 % (20 mg tiw
panobinostat), 77.8 % (25 mg tiw panobinostat), and 100 %
(30 mg tiw panobinostat), respectively (Table 4 and Fig. 3).
Association of panobinostat exposures with diarrhea
in the B2207 study
In the B2207 study dose-escalation phase, at the lower
bortezomib dose of 1.0 mg/m2 biw and 10 mg or 20 mg tiw
panobinostat, no grade 3 or 4 diarrhea was seen (Table 4 and
Fig. 3). At the higher bortezomib dose of 1.3 mg/m2 biw, the
incidences of grade 3 or 4 diarrhea were 23.5, 22.2, and
14.3 % for the panobinostat doses of 20, 25, and 30 mg tiw,
respectively. The absence of grade 3 or 4 diarrhea with 20 mg
panobinostat and 1.0 mg/m2 bortezomib (n=7) and their
emergence (23.5 %) with 20 mg panobinostat and 1.3 mg/
m2 bortezomib (n=17) implicates bortezomib’s contribution
in this particular AE, even though the observation was based
on a very small sample size. During the dose-expansion phase
that used 2 weeks on and 1 week off dosing schedule with
1.3 mg/m2 bortezomib, the rate of grade 3 or 4 diarrhea was
20 %.
Key grade 3 or 4 AEs from B2207, PANORAMA-1 com-
bination studies and single-agent studies are summarized in
Table 5. Though panobinostat exposure is lower in the 2 com-
bination studies, the toxicities are higher. For example, grade 3
or 4 thrombocytopenia occurrence in single-agent studies was
about 21%, whereas it was 81% in the B2207 study and 57%
in the PANORAMA-1 study. Grade 3 or 4 diarrhea was about
3 % in single-agent studies, whereas it was 16 % in the B2207
study and 26 % in the PANORAMA-1 study. The difference
in the rates of AEs in the combination studies compared to
single-agent studies could be attributed to overlapping toxic-
ities with bortezomib (Table 5).
Discussion
Three different analyses of panobinostat exposure-response
derived from 2 clinical trials were carried out. Initially, the
Table 3 Panobinostat PK parameters for single-agent studies vs combination studies
PK parameters 20 mg PAN single agent
(tiw qw)
N=32
B2207 cycle 2 day
8 PAN+BTZ+Dex
N=12
PANORAMA-1 cycle 1 day
8 PAN+BTZ+Dex
N=12
Tmax (h) 1 (0.5–8) 1 (0.5–6.3) 2.02 (0.5–4.0)
Cmax (ng/mL) 21.6 (83) 8.1 (90.3) 15.3 (39.0)
AUC0-24 (ng h/mL) 139 (71) 47.5 (76.8) 95.2 (28.4)
T1/2 (h) 16.9 (33) 15.9 (29.2) 16.7 (21.0)
CL/F (L/h) 99.8 (53) 285.2 (79.4) 147.6 (30.8)
Vz/F (L) 2337 (53) 6539 (81) 3553 (32)
Values are median (range) for Tmax and geometric mean (% coefficient of variation, CV) for all other parameters
N is the number of patients having an eligible record of multiple oral dose, AUC area under the curve, CL/F oral clearance, Cmax maximum plasma
concentration, Tmax time to reach Cmax, T1/2 half-life of panobinostat, Vz/F apparent volume of distribution
Fig. 3 Exposure-response relationship – B2207
Fig. 2 Exposure comparison between PANORAMA-1 and B2207
patients
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effect of 20 mg dexamethasone on panobinostat exposure was
analyzed. Next, the association of panobinostat exposure to
rate of response was assessed, and finally, the association of
panobinostat exposure to rates of key AEs was determined.
Dexamethasone effect
A prior study in healthy volunteers showed that 8 mg oral
dexamethasone given twice daily for 5 days caused an in-
crease in CYP3A4 activity by approximately 25 % [20]. Iso-
lated hepatocyte cultures treated with increasing concentra-
tions of dexamethasone (2–250 μM) showed an increase of
CYP3A4 activity from 1.7 to 6.9-fold [20]. Another study in
primary human hepatocytes in culture showed a biphasic in-
duction of CYP3A4 mRNA due to dexamethasone [21]. At
low concentrations (below 100 nM), dexamethasone induces
the nuclear protein pregnane X receptor expression, and this in
turn transactivates CYP3A4 mRNA. At higher concentrations
(up to 100 μM), dexamethasone directly activates the
pregnane X receptor, with a concurrent increase in CYP3A4
mRNA [21]. This is represented in Fig. 4 (adapted with per-
mission). At the 20mg oral dose of dexamethasone used in the
B2207 study, the projected Cmax for dexamethasone is ap-
proximately 30 nM. Another pharmacokinetic study using
20 mg panobinostat in combination with 25 mg lenalidomide
and 40 mg dexamethasone (day 1 through day 4) showed a
further decrease of approximately 60 % in PAN exposure
compared to historical single-agent data (unpublished data).
Since the fraction of panobinostat metabolized through
Table 4 Summary of data on efficacy, exposure, and grade 3 or 4 adverse events (thrombocytopenia and diarrhea) in the B2207 study












(2 weeks on/1 week off)
+BTZ 1.3 mg/
m2+D×20 mg
1.0 mg/m2 mg/m2 mg/m2 mg/m2 mg/m2
N=7 N=7 N=17 N=7 N=9 N=15
AUC0-24 (ng h/mL)
cycle 1 day 8
24.1 (33.0) 87.5 (100.2) 89.1 (58.8) 102.8 (45.0) 106.4 (31.6) 61.8 (60.9)
Cmax (ng/mL)
cycle 1 day 8




6 (85.7) 6 (85.7) 14 (82.4) 7 (100) 7 (77.8) 10 (66.7)
ORR n (%) and 95 %
CI
1 (14.3) 2 (28.6) 9 (52.9) 4 (57.1) 5 (55.6) 11 (73.3)
[0.4, 57.9] [3.7, 71] [27.8, 77.0] [18.4, 90.1] [21.2, 86.3] [44.9, 92.2]
Grade 3/4, diarrhea,
n (%)
0 0 4 (23.5) 1 (14.3) 2 (22.2) 3 (20.0)
Values are given as geometric mean (% CV) for AUC0-24 and Cmax
ORR objective response rate
Table 5 Selected grade 3 or 4 adverse events from single-agent studies





















Anemia 29 (9) 11 (18) 63 (17)
Neutropenia 42 (14) 17 (27) 92 (24)
Thrombocytopenia 66 (21) 50 (81) 217 (57)
Diarrhea 10 (3) 10 (16) 97 (26)
Nausea 6 (2) 0 21 (6)
Vomiting 4 (1) 3 (5) 28 (7)
Fatigue 13 (4) 7 (11) 65 (17)
Fig. 4 Biphasic induction of CYP3A4 by dexamethasone. CYP3A4
cytochrome P450, isoform 3A4, DEX dexamethasone, RIF rifampicin a
linear inducer of CYP3A4. Fig. 4 is adapted with permission from
Pascussi, JM, et al. (2001) Eur J Biochem 268:6346–6358
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CYP3A is approximately 40 % [10], it is susceptible to in-
ducers of CYP enzymes including dexamethasone. The reduc-
tion of panobinostat plasma exposure in combination with
dexamethasone confirmed this hypothesis [10].
In the current study, both the combination trials (B2207 and
PANORAMA-1) reported lower levels of panobinostat plas-
ma exposure than historical single-agent studies through re-
duced bioavailability that should be the result of increased
first-pass metabolism. Thus, drug–drug interaction with dexa-
methasone needs to be considered for drugs whose major
metabolic pathways involve cytochrome P450 enzymes in
clinical trials to avoid exposing patients to subtherapeutic
doses since dexamethasone is the backbone therapy in many
combinations for multiple myeloma.
Exposure-response analysis
In the dose escalation part of the B2207 trial, the ORR in-
creased with the increase in bortezomib or panobinostat expo-
sure. Maximum ORR for panobinostat/bortezomib combina-
tion (77.3 %) was achieved upon addition of dexamethasone
in the dose-expansion phase. This was in spite of a change in
dosing schedule (2 weeks on and 1 week off).
It is worth noting that ORR-AUC relationship in the esca-
lation phase of B2207 trial appears to follow a sigmoidal
Emax curve. However, there was an approximately 20 % in-
crease in ORR when 20 mg panobinostat was combined with
1.3 mg/m2 bortezomib, instead of 1.0 mg/m2 (Fig. 3). A lower
dose of panobinostat (10 mg) with 1.3 mg/m2 of bortezomib is
planned to be tested in future trials to see if it could increase
the response as the data suggests. The dose of 10 mg
panobinostat administered tiw in combination with 1.3 mg/
m2 bortezomib may provide a unique balance between effica-
cy and toxicity.
Analysis of exposure and key toxicities
Thrombocytopenia is a known toxicity of most pan-histone
deacetylase inhibitors and may compromise the options for
combination therapies in cancer patients. In the 2 combination
trials, the dose of bortezomib impacts the rate of severe throm-
bocytopenia. In the PANORAMA-1 trial, as subset analysis of
102 patients who completed both treatment phases of
panobinostat plus bortezomib plus dexamethasone therapy,
the occurrence of grade ≥3 thrombocytopenia reduced from
47% in treatment phase 1 (that used twice weekly bortezomib
dose), to 6 % in treatment phase 2 (that used once weekly
bortezomib dose) [22]. An earlier dose-escalation study of
panobinostat alone in patients with advanced hematologic ma-
lignancies reported 55 % grade ≥3 thrombocytopenia [12].
Recent data suggest that thrombocytopenia may be a down-
stream event of histone acetylase inhibition at bone marrow
[23]. Thus, thrombocytopenia may be used as a biomarker for
target inhibition and dose/regimen optimization.
In patients treated with bortezomib alone, data indicate that
incidences of diarrhea were sensitive to bortezomib Cmax. An
analysis by Moreau et al. of IV vs subcutaneous (SC) treat-
ment of single-agent bortezomib in patients with multiple my-
eloma showed that diarrhea is sensitive to bortezomib Cmax
[24]. Patients treated with 1.3 mg/m2 SC bortezomib had a
lower mean (SD) Cmax 20.4 (8.87)ng/mL, and 2 % grade ≥3
diarrhea, whereas patients treated with 1.3 mg/m2 IV
bortezomib had higher mean (SD) Cmax 223 (101)ng/mL,
and 5 % grade ≥3 diarrhea [24]. Diarrhea is one of the over-
lapping toxicities between bortezomib and panobinostat and is
sensitive to bortezomib exposure. Decrease in incidences of
diarrhea was seen in the PANORAMA-1 trial upon reducing
bortezomib dose to once weekly schedule [25]. Thus, future
clinical management of key AEs may be facilitated by dose
adjustments and dose reductions.
This study summarizes key analyses of panobinostat phar-
macokinetics that will be useful in the treatment of patients with
relapsed and refractory multiple myeloma. To date, pharmaco-
kinetics of panobinostat in combination with bortezomib and
dexamethasone is very limited, and exposure–response relation-
ship of panobinostat in this combination has not been published.
Given the constrains of limited exposure, this study attempted to
demonstrate that dexamethasone, which is the backbone ofmost
therapeutic regimens for multiple myeloma, reduces the plasma
concentration of panobinostat, 40 % of which is metabolized by
CYP 3A4 enzyme. An alternative regimen of once weekly
bortezomib is being increasingly used in clinical practice and,
at present, represents the standard schedule recommended for
elderly patients leading to corresponding change in dexametha-
sone dose and schedule. Characterization of panobinostat PK in
such combinations will be necessary to enable the establishment
of exposure–response correlation and provide clinical guideline
on its use. This study highlights the importance of understand-
ing drug–drug interactions in combination therapy regimens.
Early considerations to exposure response relationships would
aid the design of pivotal phase 3 trials.
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